Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclobenzaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.97 |
| ▸ | HTR2B | P41595 | 6/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.97 |
| ▸ | DRD2 | P14416 | 6/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.97 |
| ▸ | DRD3 | P35462 | 6/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobenzaprine SCHEMBL4964925 | 1.00 | LMNA (1.00) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL29350662 | 1.00 | LMNA (1.00) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL4606463 | 0.98 | LMNA (0.97) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL7654526 | 0.98 | HRH1 (1.00) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL38527 | 0.98 | HRH1 (1.00) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL29520569 | 0.98 | HRH1 (1.00) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL1649752 | 0.95 | HRH1 (0.93) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL17812812 | 0.92 | LMNA (0.85) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL17812696 | 0.90 | HRH1 (0.84) | LMNAPMP22MEN1KMT2AAPEX1 | |
| Cyclobenzaprine SCHEMBL29015268 | 0.89 | HRH1 (0.82) | LMNAPMP22MEN1KMT2AAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3566 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108477-A1 | CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA | TONIX PHARMA LTD (IE) | 2026-04-23 | — | — | US | claimed |
| US-20250360093-A1 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE | TONIX PHARMA LTD (IE) | 2025-11-27 | — | — | US | claimed |
| US-20250322926-A1 | EARLY ONSET RESPONSE, FAVORABLE TOLERABILITY, AND SIDE EFFECT PROFILE IN THE TREATMENT OF FIBROMYALGIA | TONIX Pharmaceuticals Holding Corp (US) | 2025-10-16 | — | — | US | claimed |
| EP-4626549-A1 | TREATMENT OF FIBROMYALGIA | UCB Biopharma SRL (BE) | 2025-10-08 | — | — | EP | claimed |
| WO-2025137348-A1 | CYCLOBENZAPRINE HCL FOR USE IN TREATING FIBROMYALGIA WITH EARLY ONSET RESPONSE AND FAVORABLE TOLERABILITY AND SIDE EFFECT PROFILE | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-120025251-A | Preparation method of cyclobenzaprine hydrochloride | 山东新时代药业有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-120025250-A | Synthesis method of cyclobenzaprine hydrochloride | 山东新时代药业有限公司 | 2025-05-23 | — | — | CN | claimed |
| EP-4543427-A1 | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-COV-2 INFECTION (PASC) | Tonix Pharmaceuticals Holding Corp. (US) | 2025-04-30 | — | — | EP | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| CN-118931541-A | Tungsten/titanium nitride etching solution for avoiding intermetallic electrochemical corrosion effect | 湖北兴福电子材料股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-5260337-A | Of cyclobenzaprene, chlorzoxanzone, or methocarbamol and their salts; muscle spasms, and tightness of muscles | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | claimed |
| US-4968507-A | SUSTAINED RELEASE OF DRUG | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | claimed |
| EP-0036138-B2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1989-10-25 | — | — | EP | claimed |
| US-4851228-A | Multiparticulate controlled porosity osmotic | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |